Company Tagline
A biotech company developing novel therapies for Alzheimer’s disease and other potential neurological diseases (ASX:ACW)
Industry Category
Business Keywords
Company Description
Actinogen Medical is a leading biotechnology company dedicated to developing innovative therapies for Alzheimer’s disease and other neurological diseases. Actinogen Medical is focused on addressing conditions associated with dysregulated brain cortisol. With a commitment to improving patient outcomes, Actinogen Medical is at the forefront of neurological research and development.
Actinogen Medical's lead compound, Xanamem, is designed to reduce the production of intracellular cortisol by inhibiting the 11β-HSD1 enzyme in the brain. This enzyme is highly concentrated in areas of the brain associated with cognitive impairment in early Alzheimer’s Disease (AD), Depression, and other neurological and psychiatric diseases. The company's research has shown statistically significant improvements in working memory and attention in healthy, older volunteers, as well as clinically significant improvements in patients with biomarker-positive mild AD.
Located in Sydney, at Suite 901, Level 9, 109 Pitt Street, Sydney, NSW 2000, AU, Actinogen Medical is actively progressing with Phase 2 trials in cognitive impairment in Alzheimer’s Disease and Depression to further confirm and characterize Xanamem’s therapeutic potential. These trials include the XanaMIA Phase 2b AD trial with 330 patients and the XanaCIDD Phase 2a trial with 160 patients, demonstrating Actinogen Medical's dedication to advancing neurological treatments. Actinogen Medical continues to innovate and lead in the biotechnology sector.
To the Manager of Actinogen Medical, we invite you to create a customized and exclusive company showcase and product listing on our platform, enhancing your visibility and commercial development.
Actinogen Medical est une entreprise biotechnologique de premier plan dédiée au développement de thérapies innovantes pour la maladie d'Alzheimer et d'autres maladies neurologiques. Actinogen Medical se concentre sur le traitement des affections associées à un dérèglement du cortisol cérébral. Avec un engagement à améliorer les résultats pour les patients, Actinogen Medical est à l'avant-garde de la recherche et du développement neurologiques.
Le principal composé d'Actinogen Medical, Xanamem, est conçu pour réduire la production de cortisol intracellulaire en inhibant l'enzyme 11β-HSD1 dans le cerveau. Cette enzyme est fortement concentrée dans les zones du cerveau associées à la déficience cognitive dans la maladie d'Alzheimer (MA) précoce, la dépression et d'autres maladies neurologiques et psychiatriques. La recherche de la société a montré des améliorations statistiquement significatives de la mémoire de travail et de l'attention chez des volontaires sains plus âgés, ainsi que des améliorations cliniquement significatives chez les patients atteints de MA légère positive aux biomarqueurs.
Située à Sydney, au Suite 901, Level 9, 109 Pitt Street, Sydney, NSW 2000, AU, Actinogen Medical progresse activement dans les essais de phase 2 sur la déficience cognitive dans la maladie d'Alzheimer et la dépression afin de confirmer et de caractériser davantage le potentiel thérapeutique de Xanamem. Ces essais comprennent l'essai XanaMIA de phase 2b sur la MA avec 330 patients et l'essai XanaCIDD de phase 2a avec 160 patients, ce qui démontre l'engagement d'Actinogen Medical à faire progresser les traitements neurologiques. Actinogen Medical continue d'innover et de jouer un rôle de premier plan dans le secteur de la biotechnologie.
Au responsable d'Actinogen Medical, nous vous invitons à créer une vitrine d'entreprise et une liste de produits personnalisées et exclusives sur notre plateforme, améliorant ainsi votre visibilité et votre développement commercial.
Key Personnel / Employees
Compare Companies Side by Side
Compare Actinogen Medical with 3 companies in Biotechnology
| Comparison Field |
Actinogen MedicalMain Company |
Alithia Life Science...View Profile |
Women of Color in Ph...View Profile |
Molecule to MedicineView Profile |
|---|---|---|---|---|
|
Founded Year
|
— | 2021 | 2015 | 2015 |
|
Company Size
|
— | 2-10 | 11-50 | 11-50 |
|
City
|
Sydney, NSW | Melbourne, Victoria | Somerset, NJ | Oxford, England |
|
Country
|
Australia | Australia | United States | United Kingdom |
|
Skills & Keywords
Comparing with main company
|
8 Total Skills
Biotechnology
Alzheimer’s Disease
Neurological Diseases
Pharmaceuticals
Clinical Research
Cortisol Regulation
Xanamem
Clinical Development
|
1 Total
1 Unique
Unique Skills:
Clinical Trials
|
27 Total
27 Unique
Unique Skills:
Accounting
CMC
Communications
Congress Management
Contracts
Digital Media
+21
|
6 Total
6 Unique
Unique Skills:
Back Office Support for Virtual & Semi-VIrtual Companies & Teams
Commercialisation
Corporate Governance
Drug Development
Drug Discovery
Due Diligence & Expert Opinion Services
|
4
Total Companies2015
Oldest Founded3
Countries42
Unique SkillsSimilar Companies
Other organizations in the same industry
Nectin Therapeutics
BiotechnologyUnlocking the power of the immune system - next-generation immunotherapy
Excision BioTherapeutics
BiotechnologyDeveloping CRISPR-based therapies intended to cure viral infectious diseases.
Ascidian Therapeutics
BiotechnologyRewriting RNA
Q Bio
BiotechnologyMaking the Star Trek MedBay a Reality
Alternative Company Names
This company is also known as